We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$671M
AUM Growth
-$749M
Cap. Flow
-$596M
Cap. Flow %
-88.74%
Top 10 Hldgs %
41.79%
Holding
248
New
39
Increased
16
Reduced
53
Closed
62

Top Buys

Rank Stock Value
1
KZR
Kezar Life Sciences
KZR
+$11.5M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$7.64M
3
CLDX icon
Celldex Therapeutics
CLDX
+$6.48M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.45M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.08M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$13.7M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.89M
3
CMPS
Compass Pathways
CMPS
+$6.85M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$5.93M
5
BCAB icon
BioAtla
BCAB
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 50.73%
2 Consumer Staples 0.3%
3 Technology 0.3%
4 Financials 0.11%
5 Real Estate 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRAW icon
176
Traws Pharma
TRAW
$6.85M
$37K 0.01%
603
– –
KNTE
177
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$35K 0.01%
+1,990
New +$42K
PDSB icon
178
PDS Biotechnology
PDSB
$38.4M
$28K ﹤0.01%
+3,495
New +$37.6K
BBIO icon
179
BridgeBio Pharma
BBIO
$15.7B
$25K ﹤0.01%
+1,500
New +$63.5K
BXRX
180
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$21K ﹤0.01%
68
– –
ICPT
181
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$18K ﹤0.01%
+1,100
New +$18.5K
FLACU
182
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$9K ﹤0.01%
941
-72,177
-99% -$723K
DCPH
183
PUT
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$8K ﹤0.01%
+800
New +$15K
KPTI icon
184
Karyopharm Therapeutics
KPTI
$43.5M
$5K ﹤0.01%
+52
New +$5.18K
BLUE
185
DELISTED
bluebird bio
BLUE
$2K ﹤0.01%
+14
New +$3.3K
TSVT
186
DELISTED
2seventy bio
TSVT
$2K ﹤0.01%
+93
New +$2.9K
ALDX icon
187
CALL
Aldeyra Therapeutics
ALDX
$92.9M
– –
-600,000
Closed -$5.27M
ALLK
188
DELISTED
Allakos
ALLK
– –
-31,526
Closed -$2.58M
APLS
189
DELISTED
Apellis Pharmaceuticals
APLS
– –
-347,545
Closed -$13.7M
APLS
190
PUT
DELISTED
Apellis Pharmaceuticals
APLS
– –
-345,400
Closed -$11.4M
ARKG icon
191
ARK Genomic Revolution ETF
ARKG
$1.57B
– –
-40,961
Closed -$3.06M
ASND icon
192
CALL
Ascendis Pharma A/S
ASND
$16B
– –
-8,400
Closed -$1.34M
AUPH icon
193
CALL
Aurinia Pharmaceuticals
AUPH
$1.91B
– –
-200,000
Closed -$4.43M
AVIR icon
194
PUT
Atea Pharmaceuticals
AVIR
$376M
– –
-22,800
Closed -$799K
AZN icon
195
CALL
AstraZeneca
AZN
$263B
– –
-50,000
Closed -$6.01M
BCAB icon
196
BioAtla
BCAB
$5.46M
– –
-3,928
Closed -$5.78M
BCRX icon
197
CALL
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-250,000
Closed -$3.59M
BCYC
198
CALL
Bicycle Therapeutics
BCYC
$269M
– –
-130,000
Closed -$5.41M
BIIB icon
199
CALL
Biogen
BIIB
$30B
– –
-167,500
Closed -$47.4M
CMPS
200
CALL
Compass Pathways
CMPS
$1.53B
– –
-848,100
Closed -$25.3M
6 7
8
9 10

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Ikarian Capital held 248 positions worth $671M, down 53% from $1.42B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital withdrew a net $596M in Q4 2021, closing 62 positions and reducing 53 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 30% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Kezar Life Sciences worth $17.1M.

  • Ikarian Capital's largest Q4 2021 buy was Kezar Life Sciences: 102,092 shares worth $17.1M.
  • Ikarian Capital added most to Zentalis Pharmaceuticals in Q4 2021, an estimated $7.64M increase.
  • Ikarian Capital's biggest Q4 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $5.93M.
  • Ikarian Capital fully exited Apellis Pharmaceuticals in Q4 2021, selling an estimated $13.7M.
  • Ikarian Capital's ten largest holdings make up 42% of its $671M portfolio in Q4 2021.
  • Ikarian Capital opened 39 new positions and closed 62 in Q4 2021.
  • Ikarian Capital's portfolio value fell 53% quarter-over-quarter to $671M.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.